COMPANY

Elevar Therapeutics

HQ: Fort Lee, NJ source · elevartx.com ↗

Status: Acquired, now part of HLB Co., Ltd. · How status works

FDA-approved therapeutic company Clinical Phase 2

8 open jobs · last seen Oct 23, 2026 · 10 sources

Location: Fort Lee, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: FGFR2 Gene Fusion/Rearrangement Gastric Cancer Adenoid Cystic Carcinoma FGFR2 Amplification FGFR2 Gene Mutation FGFR2 Gene Translocation FGFR2 Gene Activation Intrahepatic Cholangiocarcinoma Cholangiocarcinoma Metastatic Colorectal Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Rivoceranib Lirafugratinib RLY-4008 YN968D1

8Open jobs 9Trials (company is sponsor)1FDA records (2 yrs)

Hiring

Title	Location (from posting)	Employer posted	First seen
Commercial Operations Manager (Remote)	United States	Oct 13, 2026	Oct 16, 2026
IT Business Partner, R&D and Compliance (Remote)	United States	Oct 13, 2026	Oct 16, 2026
Human Resources Business Partner (Remote)	United States	Sep 10, 2026	Oct 16, 2026
Staff Accountant (Remote)	United States	Sep 3, 2026	Oct 16, 2026
Senior Director, Commercial & FP&A Finance (Remote)	United States	Sep 3, 2026	Oct 16, 2026

See all 8 jobs

Trial and FDA signals

Drug approval + hiring FDA novel approval for LYRFIGTU (NDA 220425, Sep 23, 2026); 2 manufacturing/quality or commercial roles open. FDA NDA 220425 (Sep 23, 2026)
Evidence (1 event)
- Sep 23, 2026 · FDA NDA 220425
  openFDA drugsfda: application_number=NDA220425; sponsor_name='ELEVAR'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260923; submission_class_code=TYPE 1; brand_name=['LYRFIGTU']
FDA complete response letter Received an FDA complete response letter (NDA 216586, letter dated Jul 9, 2026); 8 roles open. FDA NDA 216586 (Jul 9, 2026)
Evidence (1 event)
- Jul 9, 2026 · FDA NDA 216586
  CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Elevar Therapeutics Inc. ATTENTION: Young-Sil (Anna) Yim Executive Director, Regulatory Affairs: Fort Lee, NJ (street omitted) Dear: Young-Sil (Anna) Yim: Please

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Sep 23, 2026 FDA FDA New drug/biologic (novel): LYRFIGTU (lirafugratinib hydrochloride) — NDA220425, Sep 23, 2026. Applicant at approval: Elevar Therapeutics Inc. source ↗
Jun 4, 2026 Trial start Phase 2: A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement source ↗
Dec 30, 2021 Trial start Phase 1: A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants source ↗
Sep 2, 2020 Trial start Phase 1/Phase 2: REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors source ↗
Jan 22, 2020 Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) source ↗
Nov 18, 2019 Trial start Phase 1: A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) source ↗
Oct 1, 2018 Trial start Phase 1/Phase 2: A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer source ↗
Dec 22, 2017 Trial start Phase 1: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer source ↗
Mar 14, 2017 Trial start Phase 3: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer source ↗
2012-04 Trial start Phase 1/Phase 2: Dose-Escalation and Safety Trial of YN968D1 source ↗

Upcoming milestones

2027-09 (ESTIMATED) · Phase 2 · A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement · NCT07359820

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07359820	A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement	Phase 2	Recruiting	Jun 4, 2026	2027-09 (estimated)
NCT04119453	A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)	Phase 2	Terminated	Jan 22, 2020	Jun 28, 2023 (actual)
NCT04526106	REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2	Completed	Sep 2, 2020	Sep 5, 2025 (actual)
NCT04073615	A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)	Phase 1	Terminated	Nov 18, 2019	May 31, 2023 (actual)
NCT03396211	A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer	Phase 1	Completed	Dec 22, 2017	Oct 28, 2020 (actual)
NCT03042611	A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer	Phase 3	Completed	Mar 14, 2017	Feb 15, 2019 (actual)
NCT05287360	A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants	Phase 1	Completed	Dec 30, 2021	Mar 16, 2022 (actual)
NCT03707028	A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer	Phase 1/Phase 2	Terminated	Oct 1, 2018	Aug 24, 2021 (actual)
NCT01497704	Dose-Escalation and Safety Trial of YN968D1	Phase 1/Phase 2	Completed	2012-04	2015-02 (actual)

FDA records (last 2 years)

Sep 23, 2026 FDA New drug/biologic (novel): LYRFIGTU (lirafugratinib hydrochloride) — NDA220425, Sep 23, 2026. Applicant at approval: Elevar Therapeutics Inc. source ↗

Open jobs 8

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Commercial Operations Manager (Remote)	United States	Oct 13, 2026	Oct 16, 2026	Not stated
IT Business Partner, R&D and Compliance (Remote)	United States	Oct 13, 2026	Oct 16, 2026	Not stated
Human Resources Business Partner (Remote)	United States	Sep 10, 2026	Oct 16, 2026	Not stated
Staff Accountant (Remote)	United States	Sep 3, 2026	Oct 16, 2026	Not stated
Senior Director, Commercial & FP&A Finance (Remote)	United States	Sep 3, 2026	Oct 16, 2026	Not stated
Associate Director, Clinical Supply Chain (Remote)	United States	Sep 3, 2026	Oct 16, 2026	Not stated
Senior Manager, Clinical Quality Assurance (Remote)	United States	Sep 3, 2026	Oct 16, 2026	Not stated
Senior Director, Quality Assurance (Remote)	United States	Sep 3, 2026	Oct 16, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Elevar Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12